THESE DOCUMENTS ARE THE PROPERTY OF BOSTON SCIENTIFIC CORP. AND SHALL NOT BE  REPRODUCED, 
DISTRIBUTED, DISCLOSED OR USED FOR MANUFACTURE OR SALE OF APPARATUS WITHOUT THE EXPRESS WRITTEN 
CONSENT OF BOSTON SCIENTIFIC CORP.  
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 Rev AF 
Page 1 of 54  
Continued Access to PREVAIL  (CAP2 ) 
Clinical Protocol  
 
IDE #G020312 
 
Sponsored By 
[CONTACT_446617], Inc (“Atritech”)  
A Subsidiary of [LOCATION_011] Scientific  
[ADDRESS_567857]. Paul, MN [ZIP_CODE] -5798  
Tel: 651 -582-2994  
lynnett.voshage -[EMAIL_8551]  
 Clinical Contributors  
Robert Shipley, Ph.D., Clinical Program  Manager  
Priya Khanchandani, Clinical Scientist
 
Coordinating Principal 
Investigator  [INVESTIGATOR_124]. Saibal Kar  
Cedars Sinai Medical Center  
([PHONE_9332]  
[ADDRESS_567858]  
Room 415E  
Los Angeles, CA  [ZIP_CODE]  
[EMAIL_8552]  
 
[CONTACT_446647]  
([PHONE_9333]  
[ADDRESS_567859]  
Santa Monica, CA  [ZIP_CODE]  
[EMAIL_8553]  
 
Original Release: January 12, 2012  
Current Version: December 12 , 2012  
 
Revision History  
Revision Number  Release Date  Section  Change  Reason for Change  
AA June 25 , 2012 N/A Migrating Atritech 
CAP2 Protocol into BSC 
Template  Alignment with BSC 
Clinical System SOPs  
AB July 2, 2012 11.6 Update to active clotting 
time (ACT)  To match ACT with that 
included in the clinical 
Directions for Use 
(DFU)  
AC July 18, 2012 Section 2 and 
9.3  Clarification to the 
Exclusion Criteria  For clarification  
AD July 27, 2012 Section 5 and Remove reference to Obturator will not be 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 2 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 3 of 54 Revision History  
Revision Number  Release Date  Section  Change  Reason for Change  
16 obturator  included in CAP2  
AE December 12, 
2012 7 & 10  
 Clarify AE collection  for 
screened failures  To address FDA requests  
AF TBD  11 & 21 Added NOAC caution 
and additional Stroke 
assessments To address DSMB 
feedback  
 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 3 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 4 of 54 2. Protocol Synopsis  
Continued Access to PREVAIL (CAP2)  
Objective(s) To provide additional information about the safety and efficacy of the 
WATCHMAN LAA Closure Technology . 
Marketing Performance Expectation  The WATCHMAN LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non -valvular atrial 
fibrillation. The WATCHMAN LAA Closure Technology is designed to prevent embolization  of thrombi that may form in the LAA, thereby 
[CONTACT_446618].  
Test Device  WATCHMAN LAA Closure Technology  
Device Sizes 21mm, 24mm, 27mm, 30mm, 33mm  
Study Design This is a prospective, non -randomized, multicenter study.  
Planned 
Number of Subjects  Initial cohort of 300 subjects, up to a maximum of 1500 subjects . 
Planned Number of Centers / Countries  [ADDRESS_567860] enrollment. It is anticipated that enrollment will be conducted over a period of two years.  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 4 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 5 of 54 Continued Access to PREVAIL (CAP2)  
Required 
Medication Therapy  Warfarin, aspi[INVESTIGATOR_248], clopi[INVESTIGATOR_7745] , heparin, antibiotics, as applicable and 
outlined within the protocol  
 
Key Inclusion Criteria  A subject may be enrolled in the study if all of the following inclusion 
criteria are met:  
1. The subject is [ADDRESS_567861] has documented paroxysmal, persistent, or permanent 
non-valvular atrial fibrillation (i. e., the subject has not been 
diagnosed with rheumatic mitral valvular heart disease)  
3. The subject is eligible for long -term warfarin therapy  
4. The subject has a calculated CHADS
2 score of 2 or greater; 
Subjects with a CHADS 2 score of 1 may be included if any of 
the following apply (according to the ACC/AHA/ESC 2006 Guidelines for the Management of Subjects with Atrial Fibrillation subjects requiring warfarin therapy) : 
• The subject is a female age 75 or older  
• The subject has a baseline Left Ventricular Ejection 
Fraction (LVEF) >  30% and < 35%  
• The subject is age 65 -74 and has diabetes or coronary 
artery disease  
• The subject is age [ADDRESS_567862] is able and willing to return for required follow -up 
visits and examinations  
Key Exclusion 
Criteria  Subjects will be excluded from  the study if they meet any of the 
following criteria:  
1. The subject requires long- term warfarin therapy (i.e., even if 
the device is implanted, the subjects would not be eligible to 
discontinue warfarin due to other medical conditions requiring 
chronic warf arin therapy). Additionally, a subject with any of 
the following is excluded:  
• Thrombosis occurring at a young age (<40 years old)  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 5 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 6 of 54 Continued Access to PREVAIL (CAP2)  
• Idiopathic or recurrent venous thromboembolism  
• Thrombosis at an unusual site (i.e., cerebral veins, 
hepatic veins, renal veins, inferior vena cava, 
mesenteric veins)  
• Family history of venous thromboembolism or of inherited prothrombotic disorder  
• Recurrence or extension of thrombosis while adequately anticoagulated 
2. The subject is contraindicated for warfarin therapy or cannot tolerate long -term warfarin therapy  
3. The subject is contraindicated or allergic to aspi[INVESTIGATOR_248]  
4. The subject is indicated for antiplatelet therapy other than aspi[INVESTIGATOR_248] (for example, a subject indicated for clopi[INVESTIGATOR_7745], prasugrel, ticlopi[INVESTIGATOR_446588]).  A subject completing a course of antiplatelet therapy may be enrolled after a [ADDRESS_567863] an 
interventional or surgical procedure in the time between the WATCHMAN device implant and 45- day TEE (e.g., 
cardioversion, ablation, cataract surgery, dental surgery)  
6. The subject had a prior stroke or TIA within the [ADDRESS_567864] has a history of atrial septal repair or has an ASD/PFO device  
9. The subject has an implanted mechanical valve prosthesis  
10. The subject suffers from [LOCATION_001] Heart Association Class IV Congestive Heart Failure at the time of enrollment  
11. The subject has symptomatic carotid disease (defined as >50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by [CONTACT_87466], ipsilateral hemispheric TIAs or ipsilateral strok e); if subject has a history of carotid stent or 
endarterectomy the subject is eligible if there is < 50% stenosis  
12. The subject’s AF is defined by a single occurrence of AF  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 6 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 7 of 54 Continued Access to PREVAIL (CAP2)  
13. The subject had a transient case of AF (i.e., secondary to 
CABG, interventional procedure, etc.)  
14. The subject’s left atrial appendage is obliterated  
15. The subject has undergone heart transplantation  
16. The subject is currently treated with antibiotics for an active 
infection   
17. The subject has a resting heart rate > [ADDRESS_567865] has t hrombocytopenia (defined as < 70,000 
platelets/mm3) or anemia with hemoglobin concentration of < 
10 g/dl (i.e., anemia as determined by [CONTACT_446619])  
19. The subject is actively enrolled in a concurrent clinical study of an investigational drug or investigational device (study specifics may be reviewed with the sponsor prior to enrollment to confirm a concurrent study will not interfere with the outcomes of this study)   
20. The subject participated in any of the following studie s: 
PROTECT AF, CAP Registry, or PREVAIL.  If the subject received a subject ID number for a prior WATCHMAN study, the subject may not be enroll ed. PROTECT AF control 
subjects may be considered for participation if they have completed [ADDRESS_567866] is excluded from the study if any of the following 
echocardiographic exclusion criteria (as assessed via TTE and TEE) are 
met: 
1. The subject has LVEF < 30%  
2. The subject has intracardiac thrombus or dense spontaneous echo contrast as visualized by [CONTACT_446620] [ADDRESS_567867] has an existing pericardial effusion > 2mm  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 7 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 8 of 54 Continued Access to PREVAIL (CAP2)  
4. The subject has a high risk patent foramen ovale (PFO) with 
an atrial septal aneurysm excursion > 15mm or length >  15mm  
5. The subject ha s a high risk PFO with a large shunt defined as 
early, within [ADDRESS_567868] has significant mitral valve stenosis (i.e., MV <1.5 
cm2) 
7. The subject has complex atheroma with mobile plaque of the descending aorta or aor tic arch  
8. The subject has a cardiac tumor  
Statistical Methods  
Primary 
Statistical 
Hypothesis  Descriptive statistics will be used for baseline, procedure and follow -up 
data collected through the study. Analyses may include, but will not be limited to, the following: procedural success, procedural complications, and incidence of stroke leading to significant disability/death  
Statistical Test 
Method  No formal pre -specified hypotheses will be tested.  
Sample Size Parameters  A sample size of up to 1500 subjects was chosen to assess incidence of rare events with a lar ge degree of precision.  The table below  provides the 
two-sided 95% confidence interval width assuming an event rate of 5%.  
Sample Size  95% CI Width  
1000  2.8%  
1250  2.5%  
1500  2.3%  
 
 
 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 8 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 9 of 54 3. Table of Contents  
1. TITLE PAGE  ........................................................................................................................ 1 
2. PROTOCOL SYNOPSIS  .......................................................................................................... 4 
3. TABLE OF CONTENTS  .......................................................................................................... 9 
3.1. Table of Figures  ...................................................................................................... 13 
3.2. Table of Tables  ....................................................................................................... 13 
4. INTRODUCTION  ................................................................................................................. 14 
i) Background  ............................................................................................................. 14 
ii) WATCHMAN Therapy  ......................................................................................... 14 
iii) WATCHMAN Clinical Study Experience  ........................................................... 14 
5. DEVICE DESCRIPTION  ....................................................................................................... 15 
i) WATCHMAN Delivery System  ............................................................................ 16 
ii) WATCHMAN Access Sheath  ............................................................................... [ADDRESS_567869] Status and Classification  .......................................................................... 23 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 9 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 10 of 54 11. STUDY METHODS  .............................................................................................................. 23 
11.1.  Data Collection  ....................................................................................................... 23 
11.2.  Stroke Assessments  ................................................................................................ 24 
11.3.  Imaging Requirements  .......................................................................................... 24 
i) Transthoracic Echocardiogram (TTE)  ................................................................ 24 
ii) Transesophageal Echocardiogram (TEE) ............................................................ 24 
11.4.  Study Candidate Baseline Screening  .................................................................... 27 
11.5.  Informed Consent  .................................................................................................. 27 
11.6.  Implant Procedure  ................................................................................................. 28 
i) Thrombus Assessment Prior to Implant  .............................................................. 28 
ii) Implant of the WATCHMAN Device  ................................................................... 28 
iii) Prior to Device Release .......................................................................................... 29 
iv) Unsuccessful Implant Attempt  .............................................................................. 29 
11.7.  Medication Regimen for the Study  ....................................................................... 29 
i) Discharge Through 45 -Day TEE  .......................................................................... 29 
ii) 45-Day TEE ............................................................................................................ 29 
iii) 6 Month Visit  .......................................................................................................... 30 
11.8.  Follow-up Procedures  ............................................................................................ 31 
i) INR Monitoring  ...................................................................................................... 32 
ii) 45-Day Office Visit  ................................................................................................. 32 
iii) 6 Month Visit  .......................................................................................................... 33 
iv) 12 Mon th Office Visit  ............................................................................................. 33 
v) Additional Telephone Visits -18 Months and 30 Months  .................................... 34 
vi) Annual Visits -2,3,4,5 Years  ................................................................................... 34 
11.9.  Study Completion  ................................................................................................... 34 
12. STATISTICAL CONSIDERATIONS  ....................................................................................... 34 
12.1.  Sample Size Justification  ....................................................................................... 34 
12.2.  Statistical Analysis  ................................................................................................. 35 
13. DATA MANAGEMENT  ........................................................................................................ 35 
13.1.  Data Collection, Processing, and Review  ............................................................. 35 
13.2.  Data Retention  ........................................................................................................ 36 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 10 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 11 of 54 14. AMENDMENTS  ................................................................................................................... 36 
15. DEVIATIONS  ...................................................................................................................... 36 
16. DEVICE /EQUIPMENT ACCOUNTABILITY  .......................................................................... [ADDRESS_567870]/ Ethics Committee  ................................................... 38 
17.4.  Sponsor Responsibilities  ........................................................................................ 39 
17.4.1.  Role of [LOCATION_011] Scientific Representatives  ................................................ 39 
17.4.2.  Sponsor Records  ........................................................................................ 40 
17.4.3.  Sponsor Reports  ......................................................................................... 40 
17.5.  Insurance ................................................................................................................. 41 
18. MONITORI NG ..................................................................................................................... 41 
19. POTENTIAL RISKS AND BENEFITS  .................................................................................... 41 
19.1.  Risks Associated with the WATCHMAN Implant & Procedure ...................... 41 
19.2.  Possible Interactions with Concomitant Medical Treatments ........................... 43 
19.3.  Risk Minimization Action s .................................................................................... 44 
19.4.  Anticipated Benefits  ............................................................................................... 44 
20. INFORMED CONSENT  ......................................................................................................... 44 
21. SAFE TY REPORTING  .......................................................................................................... 45 
21.1.  Adverse Event Reporting  ...................................................................................... 45 
i) Adverse Event Definitions ..................................................................................... 46 
21.2.  Stroke Reporting  .................................................................................................... 47 
21.3.  Device Thrombus ................................................................................................... 48 
21.4.  [LOCATION_011] Scientific Device Deficiencies .................................................................... 48 
21.5.  Reporting to Regulatory Authorities / IRBs / ECs / Investigators  .................... [ADDRESS_567871] Implant  .................................................................... 31 
Table 11.8- 1 Visit Windows  ................................................................................................... 31 
Table 12.1- 1 Two -Sided Confidence Interval by [CONTACT_115433]  ............................................... 35 
Table 17.2.3 -1 Required Investigator Reports  ........................................................................ 38 
Table 17.4.3 -1 Required Sponsor Reports  .............................................................................. 40 
Table 25- 1 Definitions  ............................................................................................................ 52 
 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 13 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 14 of 54 4. Introduction  
i) Background  
Atrial fibrillation (AF) is one of the most common abnormal rhythm disturbances and affects 
approximately 5.5 million people worldwide, including 10% of people older than [ADDRESS_567872] debilitating consequence of AF is thrombus formation from stagnant blood flow 
leading to thromboembolism and stroke.  As such, the rate of ischemic stroke attributed to 
non-valvular AF is estimated to average 5% per year which is 2 -7 times that of those without 
AF2. 
Treatment with warfarin therapy for the prevention of thromboemboli originating in the left atrial appendage has been well documented .
3,4,5 Warfarin therapy targeting an International 
Normalized Ratio (INR) between 2.0 – 3.[ADDRESS_567873] majority 
of thrombi originates in AF patients.  This device may provide an alternative to warfarin therapy in non- valvular AF patients who require thromboembolic protection.  
ii) WATCHMAN Therapy  
The WATCHMAN
® Left Atrial Appe ndage Closure Technology is intended for patients with 
non-valvular atrial fibrillation who require treatment for potential thrombus formation and 
are eligible for warfarin therapy.  
The implanted component of the system, hereafter referred to as the WATCHMAN device, is a novel device designed to prevent the embolization of thrombi that may form in the left atrial appendage (LAA).  The WATCHMAN device may prevent the occurrence of isch emic 
stroke and systemic thromboembolism in patients with non- valvular atrial fibrillation (AF) 
who require treatment for potential thrombus formation.  It may also reduce the risk of life -
threatening bleeding events such as hemorrhagic stroke as seen in patients on warfarin therapy.  The WATCHMAN is manufactured by [CONTACT_446617], a subsidiary of [LOCATION_011] Scientific, received CE Mark in October 2005 and is under IDE in the [LOCATION_002] (U.S.).   
iii) WATCHMAN Clinical Study Experience  
Clinical evaluation of the WATCHM AN LAA Closure Technology has been ongoing since 
2002, with all U.S. studies conduct ed under IDE #G020312. Table [ADDRESS_567874] AF, demonstrated non- inferiority of the WATCHMAN device to long -term warfarin therapy 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 14 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 15 of 54 for the primary efficacy endpoint of stroke, systemic embolism and cardiovascular death.  
The Pre -Market Application (PMA) was therefore submitted to FDA in August 2008.  The 
FDA requested that a second pi[INVESTIGATOR_446589].  The second pi[INVESTIGATOR_2397], PREVAIL, was conducted to provide additional information on the implant procedure and complication rates associated with the device.  When available, the results from the PREVAIL study will be submitted to FDA in a Pre-Market Application for consideration of commercial approval of the WATCHMAN 
device in the U.S.  This continued access study will permit availability of the device to investigators and subjects during the preparation and FDA review of the Pre -Market 
Application.  
Table 4- 1 U.S. Clinical Studies of the WATCHMAN Device  
Study  Dates of Enrollment  Enrolled 
Subjects  Sites  Follow -Up 
Pi[INVESTIGATOR_2268]  
(feasibility study)  Aug 2002 –  Jan 2005  66 8 U.S. subjects completed 5 
years; OUS subjects ongoing  
PROTECT AF  
(pi[INVESTIGATOR_2397])  Feb 2005 –  Jun 2008  800 59 Ongoing through 5 years  
CAP Registry  Aug 2008 – Jun 2010  566 26 Ongoing through 5 years  
PREVAIL  
(pi[INVESTIGATOR_2397])  Nov 2010 –  Ongoing at time 
of protocol development  Up to 475  Up to 50  Ongoing through 5 years  
5. Device Description 
The WATCHMAN device is designed to be permanently implanted at or slightly distal to the ostium (opening) of the LAA to prevent embolization of blood clots formed within the trabeculated LAA.  The placement procedure can be performed under general or consc ious 
sedation in a catheterization or electrophysiology ( EP) laboratory setting using standard 
trans -septal technique under fluoroscopic and echocardiographic guidance.  
The WATCHMAN LAA Closure Technology is a three -component system which includes 
the WATCHMAN LAA Closure Device (WATCHMAN device), the WATCHMAN Delivery System and the WATCHMAN Access Sheath.  
i) WATCHMAN De vice 
The WATCHMAN device is comprised of a self -expanding nitinol frame structure with 
fixation barbs around the device perimeter and a permeable polyester fabric that covers the atrial facing surface of the device ( Figure 5 -1).  The device is constrained within the 
Delivery System unt il deployment into the LAA.  
The WATCHMAN device is available in various sizes to accommodate a range of LAA ostial diameters.  The device size, measured in mm, is the diameter of the device at its maximum dimension in an uncompressed (fully expanded) stat e.  An appropriate device size 
is selected based on LAA measurements obtained utilizing Fluoroscopy and Transesophageal Echocardiography (TEE). 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 15 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 16 of 54 Figure 5- 1 WATCHMAN Device  
 
ii) WATCHMAN Delivery System  
The delivery catheter consists of  an inner core wire with a reinforced braided jacket that is 
connected to the deployment knob at the proximal end and a screw thread assembly at the 
distal end.  The outer sheath has an overall profile of 12F.  
The WATCHMAN device is pre- loaded and is depl oyed by [CONTACT_446621].  The WATCHMAN device can be partially 
recaptured and redeployed if the device is too distal.  If the device is deployed too proximal, it can be fully recaptured. The device  is released by [CONTACT_446622]. 
iii) WATCHMAN Access Sheath  
The 14F transseptal Access Sheath is utilized to gain access to the LAA and serves as a conduit for the Delivery System.  The distal end of the Access Sheath is a vailable in various 
curve styles to assist with placement of the sheath into the LAA.  Various curve styles allow for coaxial placement of the sheath into the LAA.  The distal tip contains a marker band for in situ visualization as well as sizing marker ba nds used to gauge if the Access Sheath is 
positioned at the appropriate depth in the LAA based on the device size selected.   
The Access Sheath and dilator are utilized to gain access to the LAA after initial transseptal access into the left atrium has been established.  Once the Access Sheath is positioned into 
the left atrium and the dilator has been removed, it then serves as a conduit for the Delivery 
System.  The Delivery System is introduced into the Access Sheath and the components snap 
together to a ct as one during device implantation.   
6. Objectives  
This Continued Access Protocol is a prospective, non- randomized, multicenter study to allow 
continued access to the WATCHMAN LAA Closure Technology during the data analysis, reporting and review of the PRE VAIL pi[INVESTIGATOR_446590] -Market Application by [CONTACT_8415].   
Subjects with non- valvular AF who require treatment for potential thrombus formation, and 
are eligible for warfarin therapy, will be screened to participate in the study.  Subjects will be screened via review of medical history, transthoracic echocardiography ( TTE) and TEE 
testing.  Once study eligibility is determined, subjects will be enrolled and implanted with the 
Released [ADDRESS_567875] enrollment for assessment of adverse events at intervals of 45 days, 6 months, 12 months, semi -annually through 3 years, and thereafter annually through 5 ye ars.  
7. Endpoint Analysis  
Descriptive statistics will be used for baseline, procedure and follow -up data collected 
through the study. Analyses may include, but will not be limited to, the following: procedural success, procedural complications, and incidence  of stroke leading to significant 
disability/death. Any adverse events associated with screened failures who have diagnostic testing to assess eligibility for the device or for device implantation, or who have medication changes  in preparation for device i mplantation will be included in the analyses.  
8. Design  
This is a prospective, non -randomized, multicenter study to provide additional information 
about the safety and efficacy of the WATCHMAN LAA Closure Technology.  
This study will be conducted at up to [ADDRESS_567876] complete the WATCHMAN training program.  Operator training includes the following elements:  
• On-line pre -study examination  
• Interactive on -line WATCHMAN case studies  
• Case observations with an experienced WATCHMAN implanting physician  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 17 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 18 of 54 • Hands -on training for implanting physicians and lab staff on the WATCHMAN 
implant procedure from preparation to implantat ion and follow -up 
8.3. Treatment Assignment  
Not Applicable  
8.4. Justification for the Study Design  
Clinical evaluation of the WATCHMAN LAA Closure Technology has been ongoing since 
2002, with all U.S. studies  conducted under IDE #G020312. The pi[INVESTIGATOR_2397], PROTECT 
AF, demonstrated non- inferiority of the WATCHMAN device to long -term warfarin therapy 
for the primary efficacy endpoint of stroke, systemic embolism and cardiovascular death.  
The Pre -Market Application (PMA) was therefore submitted to FDA in August 2008.  The 
FDA requested that a second pi[INVESTIGATOR_446591].  The second pi[INVESTIGATOR_2397], PREVAIL, was conducted to provide additional information on the implant procedure and complication rates associated with the device.  When available, the results from the PREVAIL study will be submitted to FDA in a Pre-Market Application for consideration of commercial approval of the WATCHMAN 
device in the U.S.  This continued access study will permit availability of the de vice to 
investigators and subjects during the preparation and FDA review of the Pre -Market 
Application.  
9. Subject Selection  
9.1. Study Population and Eligibility  
The eligibility criteria for this continued access study are the same as the PREVAIL pi[INVESTIGATOR_2397].  All subjects who present with non- valvular AF and are eligible for warfarin therapy 
will be considered for inclusion into the study.  Those subjects who fulfill the inclusion criteria, do not meet any of the exclusion criteria, and provide written consent will be invited to participate.  Qualified subjects will undergo TTE and TEE testing to further determine eligibility for the study.  Only subjects meeting all criteria will be enrolled.   
CHADS
2 Eligibility Criteria  
The CHADS 2 score will be calculated f or potential subjects as a basis for inclusion into the 
study.  Subjects with a CHADS 2 score of 2 or greater are permitted in the study as well as 
some subjects with a CHADS 2 score of 1 as described in the Inclusion Criteria. The CHADS 2 
score is calculated  using the following stroke risk factors:  
• 1 point is assigned for documented congestive heart failure (defined as having 
recent heart failure -related symptoms, within the previous 100 days, and the 
presence of moderate or severe left ventricle systolic dysfunction on 
echocardiography)  
• 1 point is assigned for documented hypertension (systolic > 160 mmHg or 
well-controlled by [CONTACT_14181] -hypertensive medication)  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 18 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 19 of 54 • [ADDRESS_567877] age of 75 years or older  
• 1 point is assigned for diabetes  
• 2 points are assigned for prior cerebral ischemic stroke or Transient Ischemic 
Attack ( TIA) 
9.2. Inclusion Criteria  
A subject may be enrolled in the study if all of the following inclusion criteria are met:  
1. The subject is [ADDRESS_567878] has documented paroxysmal, persistent, or permanent non- valvular 
atrial fibrillation (i.e., the subject has not been diagnosed with rheumatic mitral valvular heart disease)  
3. The subject is eligible for long -term warfarin therapy  
4. The subject ha s a calculated CHADS
2 score of 2 or greater; Subjects with a 
CHADS 2 score of 1 may be included if any of the following apply (according to 
the ACC/AHA/ESC 2006 Guidelines for the Management of Subjects with Atrial Fibrillation subjects requiring warfarin therapy) :  
• The subject is a female age 75 or older  
• The subject has a baseline Left Ventricular Ejection Fraction (LVEF) >  
30% and < 35%  
• The subject is age 65 -74 and has diabetes or coronary artery disease  
• The subject is age [ADDRESS_567879] is able and willing to return for required follow -up visits and 
examinations  
  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 19 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 20 of 54 9.3. Exclus ion Criteria  
Subjects will be excluded from the study if they meet any of the following criteria:  
1. The subject requires long- term warfarin therapy (i.e., even if the device is 
implanted, the subjects would not be eligible to discontinue warfarin due to othe r 
medical conditions requiring chronic warfarin therapy). Additionally, a subject 
with any of the following is excluded:  
• Thrombosis occurring at a young age (<40 years old)  
• Idiopathic or recurrent venous thromboembolism  
• Thrombosis at an unusual site (i.e., cerebral veins, hepatic veins, renal 
veins, inferior vena cava, mesenteric veins)  
• Family history of venous thromboembolism or of inherited prothrombotic disorder  
• Recurrence or extension of thrombosis while adequately anticoagulated  
2. The subject is contrain dicated for warfarin therapy or cannot tolerate long -term 
warfarin therapy  
3. The subject is contraindicated or allergic to aspi[INVESTIGATOR_248]  
4. The subject is indicated for antiplatelet therapy other than aspi[INVESTIGATOR_248] (for example, a subject indicated for clopi[INVESTIGATOR_7745], prasugr el, ticlopi[INVESTIGATOR_446592]).  A subject completing a course of antiplatelet therapy may be enrolled after a [ADDRESS_567880] an interventional or surgical procedure in the time between the WATCHMAN device implant and 45 -day TEE (e.g., 
cardioversion, ablation, cataract surgery, dental surgery)  
6. The subject had a prior stroke or TIA within the [ADDRESS_567881] has a history of atrial septal repair or has an ASD/PFO device 
9. The subject has an implanted mechanical valve prosthesis  
10. The subject suf fers from [LOCATION_001] Heart Association Class IV Congestive Heart 
Failure at the time of enrollment 
11. The subject has symptomatic carotid disease (defined as >50% stenosis with 
symptoms of ipsilateral transient or visual TIA evidenced by [CONTACT_87466], 
ipsila teral hemispheric TIAs or ipsilateral stroke); if subject has a history of 
carotid stent or endarterectomy the subject is eligible if there is < 50% stenosis  
12. The subject’s AF is defined by a single occurrence of AF  
13. The subject had a transient case of AF ( i.e., secondary to CABG, interventional 
procedure, etc.)  
14. The subject’s left atrial appendage is obliterated  
15. The subject has undergone heart transplantation  
16. The subject is currently treated with antibiotics for an active infection   
17. The subject has a restin g heart rate > [ADDRESS_567882] has thrombocytopenia (defined as < 70,000 platelets/mm
3) or anemia 
with hemoglobin concentration of < 10 g/dl (i.e., anemia as determined by [CONTACT_446623])  
Released [ADDRESS_567883] is actively enroll ed in a concurrent clinical study of an investigational 
drug or investigational device (study specifics may be reviewed with the sponsor 
prior to enrollment to confirm a concurrent study will not interfere with the outcomes of this study)   
20. The subject par ticipated in any of the following studies: PROTECT AF, CAP 
Registry, or PREVAIL.  If the subject received a subject ID number for a prior 
WATCHMAN study, the subject may not be enrolled. PROTECT AF control 
subjects may be considered for participation if th ey have completed [ADDRESS_567884] is excluded from the study if any of the following echocardiographic exclusion 
criteria (as assessed via TTE and TEE) are met:  
1. The subject has LVEF < 30%  
2. The subject has intracardiac thrombus or dense spontaneous echo contrast as visualized by [CONTACT_446620] [ADDRESS_567885] has an existing pericardial effusion > 2mm  
4. The subject has a high risk patent foramen ovale (PFO) with an atrial septal aneurysm excursion > 15mm or length >  15mm  
5. The subject has a high risk PFO with a large shunt defined as early, within [ADDRESS_567886] has significant mitral valve stenosis (i.e., MV <1.5 cm
2) 
7. The subject has complex atheroma with mobile pl aque of the descending aorta or 
aortic arch  
8. The subject has a cardiac tumor  
10. Subject Accountability  
10.1. Enrollment  
All adult subjects with non -valvular AF who require treatment for potential thrombus 
formation and are eligible for warfarin therapy shall initially be screened as candidates for the study.  Subjects receiving dabigatran or rivaroxaban prior to enrollment may be considered for inclusion in the study however they will be required to be treated with warfarin post -WATCHMAN implant. Those subjects who provide consent and meet the 
Inclusion and Clinical Exclusion Criteria will undergo an echocardiographic examination (TTE and TEE) to further evaluate Echo Exclusion Criteria.   
If the baseline TEE confirms the presence of any intracardiac thrombus, the sub ject cannot be 
enrolled in the study.  The subject may be treated with anticoagulation therapy and, after an appropriate period of time, return for another baseline TEE to assess evidence of intracardiac 
Released [ADDRESS_567887] meets all of the entrance criteria he/she is considered enrolled at the time of 
venous access for the implant procedure and must  be implanted within [ADDRESS_567888] Enrollment Overview  
 
Inclusion/Exclusion criteria NOT met.  
(Screen Failure ) 
Inclusion/Exclusion criteria met  
Echocardiographic 
exclusion criteria 
assessed  
Baseline TTE and 
TEE  
 
All criteria met  
Criteria NOT met - Screen 
Failure ( AEs associated with  
diagnostic testing to assess 
eligibility for the device or for 
device implantation, or 
medication changes  in 
preparation for device 
implantation will be followed 
for 45 days from A E onset or 
until the AE is resolved.  
 
Anticoagulation 
therapy for thrombus 
treatment; repeat all 
required baseline 
testing and TEE.  
Patient does not 
qualify for study 
Enrollment  
Implant must occur within 2 
calendar days of baseline 
TEE 
Potential patient; Informed consent obtained  
Thrombus 
on TEE  
 Device Not 
Implant ed 
Follow through 45-
day visit and/or until 
any AE s resolve  
Device Implanted  
Follow per schedule  
Released [ADDRESS_567889] does decide to withdraw from the study, every effor t should be made to obtain full information on 
any ongoing adverse events.  Subjects will be given the following withdrawal options:  
1) Telephone contact [CONTACT_446624]  
2) Telephone contact [CONTACT_446625] 
3) No contact  
[CONTACT_446626] -up after significant effort has been made to 
contact [CONTACT_423].  At a minimum there should be [ADDRESS_567890]’s last known residence.  
Subjects with unsuccessful implant attempts should be followed through the 45- day visit for 
any adverse events or followed through the resolution of existing adverse events, whichever is later, and then be withdrawn from the study.  
Subject withdrawal and lost to follow -up will be documented on the End of Study case report 
form.  
10.3. Subject Status and Classification  
• Consent Ineligible/Screen Failure: A subject who has signed the informed consent but is found to not meet the eligibility criteria, and does not undergo an implant.  
• Unsuccessful Implant Attempt: A subject who meets all the eligibility criteria, is 
conside red enrolled at the time of venous access at the beginning of an implant 
attempt but does not receive an implant. If the device is not successfully implanted, the post procedure medication regimen will be administered per physician discretion.   The subject  will be followed in the study through the 45- day follow -up 
visit or through resolution of any peri -procedural adverse events, whichever is later.    
• Implant: A subject who receives an implant.  
11. Study Methods  
11.1. Data Collection  
To ensure data quality and comple teness, all required data will be recorded on case report 
forms (CRFs) provided by [CONTACT_456].  Data will be entered onto electronic case report forms by [CONTACT_446627].  Case Report Forms should be completed accurately and completel y during and in a timely manner after any visit in the study.  The 
Principal Investigator [INVESTIGATOR_446593] 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 23 of 54
  Confidential 
   
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM 90884521 RevAF 
Page 24 of 54 certifying their accuracy.  Completed case report forms are to be submitted to the sponsor 
within two weeks of completion of a study visit.  
11.2. Stroke Assessments  
Three stroke assessment scales will be routinely collected at baseline and follow -up visits for 
all subjects.  These scales include the following:  
• National Institutes of Health Stroke Scale (NIHSS):  The NIHSS is an assessment tool which quantifies stroke related neurological deficit.  This assessment must be conducted in person to provide valuable information on stroke severity.  This test will 
be performed at baseline and at all office visits.  It must be conducted by a neurologist 
or personnel who have a current certification to conduct the NIHSS.  
• Modified Rankin Scale (MRS): This scale assesses the severity of stroke disability and functional dependence of subjects. This test will be collected at baseline and all 
office and telephone follow -up visits.  The assessment must be performed by [CONTACT_5640] a 
neurologist or personnel who have completed a certification for the MRS.    
• Barthel Index:  The Barthel Index quantifies a subject’s ability to perfo rm typi[INVESTIGATOR_446594].  This test will be collected at baseline and all office and telephone 
follow -up visits.  
11.3. Imaging Requirements  
All subjects will undergo a baseline TEE and TTE and follow -up TEE at the [ADDRESS_567891] 
initials should be cle arly identified on the disks.  
i) Transthoracic Echocardiogram (TTE)  
All TTEs will be conducted according to the Imaging Manual.  The baseline TTE will be 
done to evaluate LVEF to confirm subject eligibility .  An LVEF value obtained from a TTE 
performed within 60 days prior to enrollment may be used.  If a significant cardiac event 
occurs after the TTE which cau ses a change in cardiac status [ i.e., major C ongestive H eart 
Failure (CHF) decompensation]  the baseline TTE should be repeated prior to enrollment . 
ii) Transesophageal Echocardiogram (TEE)  
All TEEs will be conducted according to the Imaging Manual.  The implant TEE will allow the investigator to obtain proper measurements of the LAA to correctly size the de vice, 
Released [ADDRESS_567892] not occurred during the implant procedure (i.e., pericardial effusion).  
The 45- day and 12- month TEEs are conducted to assess flow through and around the 
WATCHMAN device and to verify there is no thrombus on the surface of the device.  As required by [CONTACT_990], some subjects may also have a 6- month TEE if the 45- day TEE 
demonstr ates inadequate seal around the device.   
Table 11.3- [ADDRESS_567893] Follow -Up 
45 Day 
Visit  6 
Month  
Visit  12 Month  
Visit  18 month 30 
month 
Telephone  Annual 
Visits  
Informed Consent  X        
Assess Inclusion/Exclusion  X        
Medical History  X        
Pregnancy Testa X        
TTE X        
TEE Xb X  X If no seal at 
45-day X   
Brain Imaging (CT/MRI) d Xc  As requiredd As requiredd As requiredd As requiredd As requiredd As requiredd 
Serum Creatinine, Platelet 
count, Hemoglobin  X        
Review Medication 
Regimen  X X X X X X X X 
Vital Signs  X   X  X  X 
NIH Stroke Scale  X   X  X  X 
Barthel Index / Modified 
Rankin  X   X X X X X 
Adverse Event Monitoring  X X X X X X X X 
a  For women of childbearing potential only  
b  Within [ADDRESS_567894] an implant attempt will be considered screening failures .  
The following will be assessed during baseline  screening and documented on the baseline 
case report forms for enrolled subjects:  
• Medical and cardiac history  
• Current medical status, vital signs and AF status  
• Pregnancy test for women of child- bearing potential  
• Laboratory analysis (hemoglobin, platelet count, serum creatinine)  
• Current medication regimen  for the use of a ntiplatelet and anticoagulation 
medications  
• Subjects with prior history of ischemic stroke, hemorrhagic stroke or TIA are 
required to have a Baseline MRI or CT obtained  
• NIH Stroke Scale, Barthel Index, and Modified Rankin Scale  
• TTE – If the subject had a TTE within [ADDRESS_567895] an appreciable difference in cardiac 
status since the TTE was performed.  
• TEE – Th e TEE must be completed prior to enrollment to confirm eligibility criteria.  
As this is an invasive screening procedure, it is recommended the TEE be performed 
at the end of the screening process.  Subjects will be implanted within [ADDRESS_567896] meets the inclusion/exclusion criteria.  Subjects must be informed about the investigational nature of the therapy and the potential benefits and risks of the WATCHMAN device prior to enrollment.  Only those subjects (or legal 
guardians) who voluntarily provide written consent to participate will be allowed to continue 
in the screening process.  A subject must receive informed consent and sign and date a 
current IRB approved consent document.  Subjects should be informed that even if they agree to participate in the study, the baseline screening and TEE may demonstrate they are not candidat es for the study.  The original, signed document is to be kept with the subject’s 
file and a copy must be provided to the subject.   
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 27 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 28 of 54 
 11.6. Implant Procedure  
i) Thrombus Assessment Prior to Implant  
Prior to implantation with the WATCHMAN device, the peri -procedural TEE should confirm 
there is no thrombus in the LAA or left atrium.  If thrombus is identified the subject may not 
be implanted and appropriate anticoagulation should be prescribed.  If venous access was 
achieved at the time a thrombus is detected, the subj ect is considered enrolled .  The subject 
may not be implanted, and will be considered an implant failure.   
If thrombus is identified prior to the implant, but without venous access, the subject will be 
considered a screening failure and may be re- screened  after the thrombus has resolved.  
ii) Implant of the WATCHMAN Device  
Investigators performing the WATCHMAN implant procedure will be chosen based on their 
familiarity with and training in currently accepted trans -septal and left heart techniques.   
The decisio n to bridge prior to the procedure with warfarin and/or heparin will be at the 
discretion of the operator. 
Antibiotics for subacute bacterial endocarditis prophylaxis are recommended for 
administration in a single dose before the procedure as outlined in t he American Heart 
Association Guideline for Prevention of Infective Endocarditis.  If the dosage of antibiotic is inadvertently not administered before the procedure, the dosage may be administered up to 2 hours after the procedure.  Refer to the Guideline s for more details (Circulation 
2007;116;1736- 1754 or current update).  
Subjects should be fully heparinized, per hospi[INVESTIGATOR_41361], throughout the procedure with a 
recommended active clotting time (ACT) of [ADDRESS_567897] be diligent in properly flushing the sheath to prevent air from becoming entrapped within the sheath and then embolizing into the systemic 
circulation.  
Reference WATCHMAN LAA Closure Technology Instructions for Use (IFU ) for complete 
information on the implant procedure and appropriate device release criteria.  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 28 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 29 of 54 
 iii) Prior to Device Release 
To ensure implant release criteria have been satisfied according to the IFU for position, size, 
stability and seal complete the following:  
• Using both fluoroscopy and TEE, confirm the implant is appropriately positioned at 
or slightly distal  to and spans the entire LAA opening (perform multiple contrast 
injections at multiple viewing angles).  
• Confirm appropriate implant size by [CONTACT_446628]/or TEE to ensure appropriate device compression 
guidelines are met.  
• Confirm acceptable implant stability by [CONTACT_746] a gentle tug on the device 
deployment knob to ensure the implant is well anchored within the LAA.  
• Confirm via fluoroscopy and TEE that all lobes are covered by [CONTACT_8121].  
iv) Unsuccessful Implant Attempt  
If the WATCHMAN device is not successfully implanted, the post procedure  medication 
regimen (See Table 11.7- 1) will be administered per physician discretion.  The subject will 
be followed in the study through the 45- day follow -up visit or through resolution of any peri -
procedural adverse events, whic hever is later.  The TEE evaluation and in -office visit are not 
necessary at the 45 -day visit for subjects without a device; these subjects may have a [ADDRESS_567898] will be exited from the study.  
11.7. Medication Regimen for the Study  
i) Discharge Through 45 -Day TEE  
Following device placement warfarin therapy should be appropriately adjusted so as to achieve a therapeutic INR of 2.0 – 3.0.  I mplanted subjects are to be on adjusted dose 
warfarin therapy through at least the [ADDRESS_567899] device placement to 
mitigate platelet aggregation.   Subjects will remain on warfarin until the 45 -day TEE 
evaluation has shown adequate seal of the LAA.   
ii) 45-Day TEE 
A TEE will be conducted at the 45 -day visit to assess position and the seal around the 
perimeter of the WATCHMAN device within the LAA ostiu m.  Adequate LAA seal is 
defined as little or no visible residual blood flow around the margins of the WATCHMAN device in either a retrograde or antegrade fashion, with jet size <  5mm.   
• If the 45- day TEE shows adequate seal of the LAA with a jet around th e device < 
5mm,  
o Warfarin therapy will be discontinued, 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 29 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 30 of 54 
 o Aspi[INVESTIGATOR_446595] 325mg indefinitely,  
o Clopi[INVESTIGATOR_446596] 6 month follow -up visit then 
discontinued, and    
o There will not be a TEE at the 6 month visit  
• If the 45- day TEE shows inadequate seal of residual LAA blood flow with a jet size > 
5mm around the margins of device,  
o The subject will remain on warfarin therapy and a [ADDRESS_567900] is on warfarin therapy, and  
o Clopi[INVESTIGATOR_446597]) [ADDRESS_567901] an inadequate seal at the 45- day TEE.   
• If the 6 month TEE shows adequate seal of the LAA with a jet around the device < 
5mm,  
o Warfarin therapy will be discontinued, and  
o Aspi[INVESTIGATOR_446595] 325mg indefinitely  
• If the 6 month TEE shows inadequate seal of residual LAA blood flow with a jet si ze 
> 5mm around the margins of device,  
o The subject will remain on warfarin therapy until a TEE can confirm adequate LAA seal, and  
o Aspi[INVESTIGATOR_446598] 81mg while the subject is on warfarin therapy  
Caution should be used if considering use of novel or al anticoagulants since this has not 
been studied in patients with a WATCHMAN device.  If anticoagulation is required for any reason beyond what is specified in the protocol, ensure medication labeling is followed; specifically that related to the abrupt d iscontinuation of NOACs in patients 
with non- valvular atrial fibrillation without adequate continuous anticoagulation.   
Released [ADDRESS_567902] Implant  
Visit Interval  Warfarin  Aspi[INVESTIGATOR_446599] – 45-Day  Yes 
Adjusted dose to 
achieve INR of 2.0 – 
3.0 Yes 
81mg while on 
warfarin  No 
LAA Seal per 45 -Day TEE  
45-Day – 6-Month  Stop  warfarin  Yes 
325mg recommended   Yes, Start  
Clopi[INVESTIGATOR_7745]  
6-Month – 5 Year  No Yes 
325mg recommended   No, Stop  Clopi[INVESTIGATOR_446600] 6 month visit  
No LAA Seal per 45 -day TEE  
45-Day – 6-Month  Yes Yes 
81mg while on 
warfarin  No 
6-Month – 5 Year  Discontinue when 
LAA seal adequate 81mg for subjects 
while on warfarin  
If no warfarin therapy, 
then adult aspi[INVESTIGATOR_248] 
(325mg) indefinitely  No 
11.8. Follow -up Procedures  
Subjects will be followed at post -enrollment intervals of [ADDRESS_567903] upon 
enrollment.  
A Follow -Up Case Report Form will be completed for each offi ce and telephone visit. Table 
11.8- 1 provides the visit ta rget visit dates and visit window ranges.   
Table 11.8- 1 Visit Windows  
Follow -up visit  Target  
(days post -implant)  Range  
 
45-Day 45 days  30-60 days  
6-Month  182 days  152-242 days  
12-Month  365 days  335-425 days  
18-Month  547 days  517-607 days  
24-Month  730 days  700-790 days  
30-Month  913 days  883-973 days  
36-Month  1095 days  1035 -1155 days  
48-Month  1460 days  1400 -1520 days  
60-Month  1825 days  1765 -1885 days  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 31 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 32 of 54 
 i) INR Monitoring  
All subjects will have INR monitoring performed at a minimum of every 28 days while on 
warfarin therapy.  Warfarin dosage should be adjusted to ensure subjects are in the therapeutic range of 2.0 – 3.0, which is standard practice for subjects with non- valvular AF. 
It is essential that investigators discuss the importance and value o f the study required INR 
monitoring schedule with study subjects.  INR values will be collected from subjects during 
follow -up visits, or directly from Coumadin Clinics, and reported by [CONTACT_446629].  
While subjects are not required to have an INR during time off warfarin therapy, careful 
attention should be given to ensure compliance to the INR monitoring requirement of at least every 28 days once warfarin is restarted.  Early discontinuation of warfarin therapy will be 
documented and the rationale  provided on the case report form.  
ii) 45-Day Office Visit  
The 45- day visit will be scheduled such that the TEE occurs within 30- [ADDRESS_567904] implant.  
Warfarin therapy and 81mg aspi[INVESTIGATOR_446601] 45- day TEE.  
During the visit a TEE will b e conducted to assess the presence of LAA blood flow through 
and around the WATCHMAN device.  If the TEE evaluation indicates complete LAA seal or 
residual blood flow around the margins of the WATCHMAN device in a retrograde or 
antegrade fashion, with jet size <  5mm, the subject will discontinue warfarin therapy and 
begin adult aspi[INVESTIGATOR_324738] (325mg) once daily for the duration of the study, unless continuing on 81mg aspi[INVESTIGATOR_446602].  Additionally, clopi[INVESTIGATOR_446603] 6 -month follow -up visit.   
Alternatively, if the TEE evaluation indicates residual LAA blood flow with a jet size > 5mm around the margins of WATCHMAN device in either a retrograde or antegrade fashion, the 
subject should continue or reinitiate warfarin therapy until such time that LAA seal occurs or a jet size <  5mm  around the WATCHMAN device is observed.  In this case aspi[INVESTIGATOR_446604] 81mg.   
Additional information collected during the 45- day visit includes the following:  
• INR values while on warfarin therapy     
• TEE to assess device position, LAA seal, thrombus on the device surface, intracardiac thrombus and residual atrial septal shunt – t o be conducted according to the Imaging 
Manual  
• NIH Stroke Scale, Barthel Index, and Modified Rankin Scale  
• Current medical status  
• Current medication regimen  
• Adverse events experienced since implant procedure  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 32 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 33 of 54 
 iii) [ADDRESS_567905] ed via telephone for those subjects with LAA seal or 
residual blood flow with jet size <  5mm around the margins of the WATCHMAN device at 
the 45- day TEE.  Subjects who had 45- day TEE evidence of LAA seal are expected to be on 
clopi[INVESTIGATOR_446605].  At completion of the [ADDRESS_567906] was unable to discontinue warfarin therapy due to jet size > 5mm at the 45 -day 
TEE, the 6 month visit will be conducted via an office visit and the TEE will be repeated to assess seal around the WATCHMAN device.  Subjects will be eligible to discontinue warfarin therapy only if the 6- month TEE confirms residual flow of <  5mm aroun d the 
device.  In this scenario, warfarin would be discontinued and an adult daily aspi[INVESTIGATOR_446606]; Clopi[INVESTIGATOR_446607] [ADDRESS_567907] implant. 
Information collected during the 6 -month visit includes the following:  
• Collection of INR values for subjects who were on warfarin therapy during this time  
• TEE (if required) to assess device position, LAA seal, thrombus on the device 
surface, intracardiac thrombus and residual atrial septal sh unt – to be conducted 
according to the Imaging Manual  
• Barthel Index and Modified Rankin Scale  
• Current medical status  
• Current medication regimen  
• Serious adverse events and adverse events experienced since previous visit  
iv) [ADDRESS_567908] implant with a TEE evaluation. Information collected during the 12- month visit includes the following:  
• Collection of INR values for any subjects who continued on warfarin therapy beyond 
the 6 month visit  
• TEE to assess device position, LAA seal, thrombus on the device surface, intracardiac 
thrombus and residual atrial septal shunt  – to be conducted according to the Imaging 
Manual  
• NIH Stroke Scale, Barthel Index, and Modified Rankin Scale  
• Current medical sta tus  
• Current medication regimen  
• Serious adverse events and adverse events experienced since previous visit  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 33 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 34 of 54 
 v) Additional Telephone Visits -18 Months and 30 Months  
All subjects will complete a telephone visit at 18 months and 30 months. 
At the 18 and 30- month visit the following information will be collected:  
• Collection of INR values for any subjects who continued on warfarin therapy after the 
last visit  
• Barthel Index and Modified Rankin Scale  
• Current medical status   
• Current medication regimen  
• Serious adverse events and adverse events experienced since previous visit  
vi) Annual Visits -2,3,4,5 Years  
All subjects will complete an office visit at annual intervals.  No additional TEEs are 
required after the 12- month visit.  Information collected during the annual off ice visits 
includes the following:  
• Collection of INR values for any subjects who continued on warfarin therapy  
• NIH Stroke Scale, Barthel Index, and Modified Rankin Scale  
• Current medical status  
• Current medication regimen  
• Serious adverse events and adverse events experienced since previous visit  
11.9. Study Completion  
Each subject will be followed for [ADDRESS_567909].  All subjects will be followed for up to 5 years or until the 
study is terminated.  Subjects enrolled in this study will be analyzed separately from the roll-in and randomized subjects enrolled in the PREVAIL study.  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 34 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 35 of 54 
 A sample size of up to 1500 subjects was chosen to assess incidence of rare events with a 
large degree of precision.  Table 12.1- 1 provides the two- sided 95% confidence interval 
width assuming an event rate of 5%.  
Table 12.1- 1 Two -Sided Confidence Interval by [CONTACT_446630]  95% CI Width  
1000  2.8%  
1250  2.5%  
1500  2.3%  
12.2. Statistical Analysis  
Analysis will include all subjects  enrolled into the study who undergo an attempted implant 
of the WATCHMAN device (i.e. undergo venous access with the intent of implanting the 
WATCHMAN device).  While no formal hypothesis tests will be performed, descriptive statistics will be generated f or the data collected at baseline, during the procedure and at 
follow -up.  For continuous variables, the mean, standard deviation, median, range and 95% 
confidence intervals will be reported.  Confidence intervals (95%) for the difference between means wil l be used to compare groups.  For proportions, 95% confidence intervals will be 
reported.  For time -to-event analyses, all subjects not having an event or are lost to follow -up 
will be censored at the time of the last documented follow -up visit.  Analyses may include, 
but will not be limited to, the following: procedural success, procedural complications, and incidence stroke leading to significant disability/death.  
13. Data Management 
13.1. Data Collection, Processing, and Review  
Subject data will be recorded in a limited access secure electronic data capture (EDC) system.  
The clinical database will reside on a production server hosted by [CONTACT_51580]. All changes made to the clinical data will be captured in an electronic audit trail and available for review by [CONTACT_5708] (BSC) or its representative. The associated RAVE software and database have been designed to meet regulatory compliance for deployment as part of a validated system compliant with laws and regulations applicable to the conduct of cli nical 
studies pertaining to the use of electronic records and signatures. Database backups are performed regularly.  
The Investigator provides his/her electronic signature [CONTACT_5760] (eCRFs) in compliance with local regu lations. A written signature [CONTACT_123375] [CONTACT_1295]. Changes to data previously submitted to the sponsor require a new electronic signature [CONTACT_3265] [CONTACT_5732] . 
Visual and/or electronic data review will be performed to identify possible data discrepancies. Manual and/or automatic queries will be created in the EDC system and will 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 35 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 36 of 54 
 be issued to the site for appropriate response. Site staff will be responsible for resolving all 
queries in the database.  
13.2. Data Retention  
The Investigator will maintain, at the investigative site, in original format all essential study 
documents and source documentation that support the data collected on the study subjects in 
compliance w ith ICH/GCP guidelines.  Documents must be retained for at least [ADDRESS_567910]. These document s will be 
retained for a longer period of time by [CONTACT_71643]. It is BSC’s responsibility to inform the Investigator when these documents no 
longer need to be maintained. The Investigator will take measures to ensure that these 
essential documents are not accidentally damaged or destroyed. If for any reason the 
Investigator withdraws responsibility for maintaining these essential documents, custody 
must be transferred to an individual who will assume resp onsibility and BSC must receive 
written notification of this custodial change.  
14. Amendments  
If a protocol revision is necessary which affects the rights, safety or welfare of the subject or 
scientific integrity of the data, an amendment is required. Appropriate approvals (e.g., IRB/EC/FDA/CA) of the revised protocol must be obtained prior to implementation.  
15. Deviations  
Per 21 CFR 812.150(a)(5) “The investigator shall notify the sponsor and the reviewing IRB of any deviation from the investigational plan to protect the life or physical well -being of a 
subject in an emergency.  Such notice shall be given as soon as possible, but in no event later than 5 working days after the emergency occurred”   
Except in an emergency, prior written approval to deviate from t he protocol should be 
obtained from the sponsor.  Any deviation from the protocol must be recorded on the protocol deviation case report form and must provide the dates of and the reasons for each deviation.  
Deviations will be reviewed and evaluated on an ongoing basis and, as necessary, appropriate corrective and preventive actions (including notif ication, center re -training, or 
discontinuation) will be put into place by [CONTACT_456].  
16. Device/Equipment Accountability  
The sponsor will provide the WATCHMAN devices and access system to the investigator.  These devices will be labeled as Investigational Use Only and will require special handling and storage controls. The devices must be kept in a secure location with restricted access.  Devices are intended for u se only by [CONTACT_9940] -investigator(s).  The investigator 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 36 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 37 of 54 
 is responsible to track the receipt, use and disposition of all investigational devices received, 
including lot/serial number and device model number.  
WATCHMAN product associated with device deficiencies should be returned to BSC for analysis.  If it is not possible to return the product, the investigator should document why the product was not returned and the final disposition of the product.  Used product not 
associated with device de ficiencies does not need to be returned to BSC but should be 
discarded according to hospi[INVESTIGATOR_41361].  Expi[INVESTIGATOR_446608].  Instruction for returning WATCHMAN prod uct is included in the study regulatory binder.  
17. Compliance 
17.1. Statement of Compliance  
This study will be conducted in accordance with ISO [ZIP_CODE]:[ADDRESS_567911] their origins in the 
Declaration of Helsinki, and pertinent individual country laws and regulations. The study shall not begin until the required approval/favorable opi[INVESTIGATOR_446609] e IRB and/or regulatory 
authority has  been obtained, if appropriate . Any additional re quirements imposed by [CONTACT_446631] , if appropriate . 
17.2. Selection of Investigators 
Investigators will be selected for this study based up on training and experience.  Investigators 
will have experience with the WATCHMAN device due to participation in previous WATCHMAN studies, PROTECT AF or PREVAIL.  
The Investigator will ensure that this study is conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and that are consistent with 
GCP and applicable regulatory (local) requirements; whichever affords the greater protection to the subject.  
17.2.1. Delegation of Responsibility  
When specific tasks are del egated by [CONTACT_2413], included but not limited to conducting 
the informed consent process, the investigator is responsible for providing appropriate training and adequate supervision of those to whom tasks are delegated. The investigator is accountabl e for regulatory violations resulting from failure to adequately supervise the 
conduct of the clinical study.  
17.2.2. Investigator Records 
The investigator is responsible for the preparation (review and signature) and retention of the 
records cited below.  Records are subject to inspection and must be retained for a period of at least two (2) years (or according to local regulatory requiremen ts) after the investigation is 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 37 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 38 of 54 
 terminated or the date that the records are no longer required for purposes of supporting 
publications or regulatory submissions. 
• All significant correspondence which pertains to the investigation 
• Subjects’ case history recor ds, including: signed subject informed consent form; all 
relevant observations; observations of adverse device events; medical history; 
completed sponsor Case Report Forms; documentation of the dates and reasons for 
any deviation from the protocol  
• Copi[INVESTIGATOR_446610]  
• Signed Investigator Agreement and recent curriculum vitae, both of which also must 
be submitted to the sponsor  
• IRB approval and discourse documentation.  A copy of the IRB approval must be 
submitted to the sponsor  
17.2.3. Investigator Reports  
Table 17.2.3- [ADDRESS_567912] (UADE)  Sponsor, IRB  Notification within ten working days after the investigator first learns of the event.
 
Withdrawal of IRB Approval
 Sponsor  Notification within five working days.  
Progress Report  Sponsor, IRB  The Investigator must submit this report at regular 
intervals, but not less than once per year.  
Deviations from Investigational Plan
 Sponsor, IRB  Repor t of any deviation from the investigational plan to 
protect the life or physical well -being of a subject in an 
emergency.  Notification within five working days.  
Device use without 
Informed consent  Sponsor, IRB  Notification within five working days after the use occurs.  
Final Report  Sponsor, IRB  Within three months of study termination or completion.  
17.3. Institutional Review Board/ Ethics Committee  
A copy of the protocol, proposed Informed Consent form, other written subject information, 
and any proposed advertising material must be submitted to the IRB for written approval.  A copy of the written IRB approval of the protocol and Informed Consent form must be received by [CONTACT_446632].  
The Investigator must submit and, where necessary, obtain approval from the IRB for all subsequent protocol amendments and changes to the Informed Consent form.  The 
Released [ADDRESS_567913] notify the IRB of deviations from the protocol or SAEs  and UADEs 
occurring at the site in accordance with local procedures.  
The Investigator is responsible for obtaining annual IRB approval and renewal throughout 
the duration of the study.  Copi[INVESTIGATOR_5699]’s reports and the IRB continuance of approval must be sent to the sponsor.  
17.4. Sponsor Responsibilities  
All information and data sent to BSC concerning subjects or their participation in this study will be considered confidential  by [CONTACT_71640]. Only authorized BSC personnel or a BSC 
representative will have access to these confidential  records. Authorized regulatory personnel 
have the right to inspect and copy all records pertinent to this study. Study data collected 
during this study may be used by [CONTACT_113644], publication, and to 
support future research and/or other business purposes. All data used in the analysis and 
reporting of this study will be without identifiable reference to specific subject name. 
[LOCATION_011] Scientific will keep subjects’ health information confidential  in accordance w ith all 
applicable laws and regulations.  [LOCATION_011] Scientific may use subjects’ health information to 
conduct this research, as well as for additional purposes, such as overseeing and improving the performance of its device, new medical research and proposal s for developi[INVESTIGATOR_123319], and other business purposes. Information received during the study will not be used to market to subjects; subject names will not be placed on any mailing lists or sold to anyone for marketing purposes.  
17.4.1. Role of [LOCATION_011] Scientific Representatives  
[LOCATION_011] Scientific personnel can provide technical support to the investigator and other health care personnel (collectively HCP) as needed during implant, testing required by [CONTACT_760], 
and follow -ups. Support may include HCP training, addressing HCP questions, or providing 
clarifications to HCPs concerning the operation of BSC equipment/devices. 
In addition, BSC personnel may perform certain activities to ensure study quality. These 
activities may include the f ollowing.  
• Observing testing or medical procedures to provide information relevant to protocol 
compliance  
• Reviewing collected data and study documentation for completeness and accuracy  
[LOCATION_011] Scientific personnel will not do the following.  
• Practice medicin e 
• Provide medical diagnosis or treatment to subjects  
• Discuss a subject’s condition or treatment with a subject without the approval and 
presence of the HCP  
• Independently collect critical study data (defined as primary or secondary endpoint data)  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 39 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 40 of 54 
 • Enter data  in electronic data capture systems or on paper case report forms  
17.4.2. Sponsor Records 
The sponsor will maintain the following records:  
• All correspondence which pertains to the investigation  
• Signed investigator agreements and curriculum vitae  
• System/procedure r elated Adverse Device Events  
• All case report forms, including samples of subject informed consents, submitted by 
[CONTACT_093]; investigational plan and report of prior investigations  
• Hospi[INVESTIGATOR_446611]  
• The sponsor will own and store the clinical data generated under this protocol  
17.4.3. Sponsor Reports  
Table 17.4.3- [ADDRESS_567914] (UADE)  FDA, IRB, Investigators
 Notification within ten working days  after Sponsor first 
learns of the event.  
Withdrawal of IRB Approval
 FDA, IRB, Investigators
 Notification within five working days after receipt of approval withdrawal.
 
Withdrawal of FDA Approval
 IRB and Investigators 
 Notification will be made within [ADDRESS_567915] that an investigator return, repair or otherwise dispose of any devices. 
 
Final Report  FDA,  IRB, 
Investigators  Sponsor will notify FDA within 30 working days of the 
completion or termination of the study.  A final report will 
be submitted within 6 months after completion or 
termination.  
Device use without informed consent
 FDA Notification will be made within 5 working days after receipt of notice from an investigator.
 
17.5. Insurance  
Where required by [CONTACT_5737]/country regulation, proof and type of insurance coverage, by [CONTACT_142219]. 
18. Monitoring  
Each clinical site will be monitored to ensure that the study is conducted in full  compliance 
with the study protocol, and in accordance with the FDA Guideline for the Monitoring of Clinical Investigations, Good Clinical Practices, and the sponsor’s policy and procedures, and the  study Monitoring Plan.   
Professionals qualified through training, education and experience will conduct the monitoring of the study.  Contact [CONTACT_446633].  
The study may also be subject to a quality assurance audit by [CONTACT_154986], as 
well as inspection by [CONTACT_4708]. It is important that the Investigator and relevant study personnel are available during on- site monitoring visits or audits and that 
sufficient time is devoted to the process.  
19. Potential Risks and Benefits 
19.1. Risks Associated with the WATCHMAN Implant & Procedure 
Potential procedural risks associated with the WATCHMAN implant procedure are similar to those encountered peri - and postoperatively for many routine catheterization procedures.  
These include, but are not limited to, the following:  
• Air embolism  
• Allergic reaction , e.g. contrast media  
• Anemia requiring transfusion  
• Anesthesia risks and complications  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 41 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 42 of 54 
 • Arrhythmias  
• Fistula , e.g. arterio venous  
• Cardiac perforation  
• Cardiac tamponade  
• Chest pain/discomfort  
• Complete heart block  
• Cranial bleed  
• Death  
• Endocarditis  
• Gastrointestinal bleeding  
• Groin puncture bleed  
• Hematoma  
• Hyper/Hypotension  
• Infection  
• Major bleeding requiring transfusion  
• Myocardial infarction  
• Pericardial effusion  
• Pleural effusion  
• Pneumothorax   
• Pseudoaneurysm  
• Pulmonary edema   
• Pulmonary embolism   
• Pulmonary vein obstruction   
• Renal insufficiency/failure  
• Respi[INVESTIGATOR_5448]/failure  
• Stroke  
• Systemic embolism  
• TEE complications , e.g. esophageal injury  
• Thromboembolism  
• Thrombosis  
• Thrombosis at septal puncture  
• Transient ischemic attack (TIA)   
• Valvular damage  
• Vascular damage  
• Vasovagal reactions  
• Wound dehiscence   
Definitions of potential procedural related complications are located in Table 25- 1. 
In addition to the aforementioned general risks, additional risks specifically 
associated with the WATCHMAN implant are as follows:  
• Additional surgery if the device is not  placed in the correct position  
• Allergic reaction to the implant materials  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 42 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 43 of 54 
 • Atrial septal shunt or iatrogenic atrial septal defect  
• Device misplacement  
• Device embolization  
• Device fracture or extrusion  
• Excessive bleeding  
• Hypertrophic scarring or thrombosed veins  
• Infection  
• Device thrombosis 
• Inability to move or retrieve device  
• Inability to implant the device  
19.2. Possible Interactions with Concomitant Medical Treatments  
Subjects who receive the WATCHMAN device may stop Warfarin therapy as early as the 
45-day follo w-up visit if they meet Warfarin cessation guidelines; therefore, at that time, 
subjects may be at an increased risk of stroke.   Warfarin is the proven standard of care for 
reducing the risk of stroke in atrial fibrillation.  The WATCHMAN device is designed to be used instead of Warfarin.  Thus, the absence of Warfarin may represent a risk, especially if 
the device is not effective in preventing stroke.   
From the Warfarin package insert, risks associated with Warfarin therapy include:  
• Major or fatal bleed ing 
• Risk factors for bleeding include: INR > 4.0, age 65 and older, high variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular 
disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, 
concomitant drugs a nd long duration of warfarin therapy   
• Hemorrhage from any tissue or organ  
• Necrosis and/or gangrene of the skin or other tissues  
• Epi[INVESTIGATOR_3940]  
• Bruising  
• Prolonged bleeding from a cut or scrape  
• Headache  
• Nausea/upset stomach  
• Vomiting  
• Diarrhea  
• Fever  
• Skin rash  
• Skin or tissue necrosis  
• Decrease in white blood cell count  
• Inability to tolerate the medication  
Released [ADDRESS_567916] 
inclusion/exclusion criteria and by [CONTACT_446634] -up of subjects are 
consistent with current medical practices.  The WATCHMAN device is constructed of well -
known, well -characterized materials and has undergone extensive mechanical functionality 
and clinical testing.  
Investigational teams selected to conduct the study will be experienced and skilled in interventional cardiology and/or electrophysiology with trans -septal and left heart 
experience, will have training on the WATCHMAN LAA closure implant procedure and will have access to modern high technology medical facilities to conduct those procedures.   
19.4. Anticipated Benefits  
The potential benefit of implanting the WATCHMAN device is its expected ability to 
prevent thromboembolic events originating in the LAA.  The WATCHMAN device may protect  against ischemic stroke and systemic thromboembolism.  In subjects implanted with 
the device, the elimination of Warfarin therapy may reduce bleeding complications, such as hemorrhagic stroke, associated with long- term anticoagulation.  Economic and subje ct 
benefits related to the elimination of life -long compliance to Warfarin therapy and the 
frequent blood tests and lifestyle changes associated with blood thinning medications are numerous.  Lastly, a device -based solution addressing the mechanism of stro ke in atrial 
fibrillation subjects may prove to be simple, tolerable and cost -effective.  
20. Informed Consent 
Subject participation in this clinical study is voluntary.  Informed Consent is required from all subjects or their legally authorized representative.  The Investigator is responsible for 
ensuring that Informed Consent is obtained prior to the use of any investigational devices, study- required procedures and/or testing, or data collection.  
The obtaining and documentation of Informed Consent must be in a ccordance with the 
principles of the Declaration of Helsinki, ISO [ZIP_CODE], any applicable national regulations, and local Ethics Committee and/or Regulatory authority body, as applicable. The ICF must be  
approved by [CONTACT_16018]’s IRB , or central IRB, if applicable.  
[LOCATION_011] Scientific will provide a study- specific template of the ICF to investigators 
participating in this study. The ICF template may be modified to meet the requirements of t he 
investigative center’s IRB/EC .  Any modification requires approval from BSC prior to use of 
the form.  The ICF must be in a language understandable to the subject and if needed, BSC will assist the center in obtaining a written consent translation. Translated con sent forms 
must also have IRB/EC  approval prior to their use.  Privacy language shall be included in the 
body of the form or as a separate form as applicable.   
The process of obtaining Informed Consent shall:  
• be conducted by [CONTACT_079] [INVESTIGATOR_5704],  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 44 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 45 of 54 
 • include a descript ion of all aspects of the clinical study that are relevant to the subject’s 
decision to participate throughout the clinical study, 
• avoid any coercion of or undue influence of subjects to participate,  
• not waive or appear to waive subject’s legal rights,  
• use native language that is non- technical and understandable to the subject or his/her 
legal representative,  
• provide ample time for the subject to consider participation and ask questions if 
necessary,  
• ensure important new information is provided to new and e xisting subjects throughout the 
clinical study.  
The ICF shall always be signed and personally dated by [CONTACT_446635]. If a legal  representative signs, the subject shall be asked to provide informed 
consent for continued participation as soon as his/her medical condition allows. The original signed ICF will be retained by [CONTACT_71657] a copy of the signed and dated document and 
any other written information must be given to the person signing the form.  
Failure to obtain subject consent will be reported by [CONTACT_71658] (e.g., FDA requirement is within 5 working days of learni ng 
of such an event). Any violations of the informed consent process must be reported as deviations to the sponsor and local regulatory authorities,  as appropriate.  
If new information becomes available that can significantly affect a subject's future healt h 
and medical care, that information shall be provided to the affected subject(s) in written form via a revised ICF or, in some situations, enrolled subjects may be requested to sign and date an addendum to the ICF. In addition to new significant informati on during the course of a 
study, other situations may necessitate revision of the ICF, such as if there are amendments to the protocol, a change in Principal Investigator, administrative changes, or following annual review by [CONTACT_1201] . The new version of th e ICF must be approved by [CONTACT_1201]/EC . 
[LOCATION_011] Scientific approval is required if changes to the revised ICF are requested by [CONTACT_282085]’s IRB/EC. The IRB/EC will determine the subject population to be re -consented. 
Study personnel should explain that even if a subject agrees to participate in the study and 
signs an Informed Consent for, TEE may demonstrate that the subject is not a suitable 
candidate for the study.  
21. Safety Reporting  
21.1. Adverse Event Reporting  
For the purpose of this study an adverse event (AE) is an untoward event related to the study, the device, or the study procedures that affects the subject’s health or safety.  For the purposes of this study an Adverse Device Effect (ADE) is an adverse event related to the use 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 45 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 46 of 54 
 of the investigational medical  device.  When reporting an AE or ADE, the investigator will 
indicate the diagnosis of the event and correlating signs and symptoms on the adverse event 
report.  Individual signs and symptoms and treatment/intervention/diagnostic testing should not be repo rted as separate adverse events, instead be reported as supporting documentation 
on the AE CRF.  Additionally, it is not necessary to report an underlying disease that was 
present at baseline (i.e., CHF, AF, hypertension, chronic anemia, etc.).  However, a ny 
increase in the severity of the underlying disease may require reporting, if at the 
determination of the investigator, it is relevant to the study.   
Adverse experiences that require reporting include any adverse event with clinical symptoms that could possibly be contributed to any of the following:  
• The WATCHMAN device  
• The WATCHMAN implant procedure  
• The use of study mandated medications including warfarin, clopi[INVESTIGATOR_446612] 
(i.e.,: gastrointestinal bleeding due to warfarin or an allergic reaction to clopi[INVESTIGATOR_7745])  
• Any study required procedures (i.e., clinical complications from protocol required 
TEE)  
• The following adverse events will also be reported:  
• Neurological events including, but not limited to, stroke, TIA or seizure which are not 
pre-study co nditions  
• Any events possibly related to the study endpoints of stroke, systemic embolization, 
death, etc.  
• Thrombosis  
• Bleeding complications requiring intervention or transfusion of blood 
• Any potential UADE  
Each adverse event will be evaluated by [CONTACT_446636].  
Definitions of procedural related complications are located in  Table 25- 1. 
i) Adverse Event Definitions 
Adverse events should meet the reporting requirements in the preceding section before 
consideration for reporting as serious events.   
Serious adverse events are to be reported to the sponsor within 1 business day of learning of 
the event.  A serious adverse event (SAE) is an event that:  
• Led to death  
• Led to serious deterioration in the health of the subject that:  
o Resulted in a life -threatening illness or injury, or  
o Resulted in permanent impairment of a body structure or a body function, or  
Released [ADDRESS_567917] hospi[INVESTIGATOR_1081], 
or 
o Resulted in medical or surgical interventio n to prevent life -threatening illness 
or injury or permanent impairment to body structure or a body function  
• Led to fetal distress, fetal death, or a congenital abnormality or birth defect  
NOTE: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a pr ocedure required by [CONTACT_12695], without serious deterioration in health, is not considered a serious adverse event. 
A serious adverse device effect (SADE) is an adverse device effect that has resulted in any of 
the consequences characteristic of a seriou s adverse event.  All SAEs that could have led to a 
SADE if suitable action had not been taken or if circumstances had been less fortunate shall be reported as required by [CONTACT_446637].  
An unanticipated adverse device effect (UADE) is any serious adverse effect on health or safety or any life- threatening problem or death caused by, or associated with a device, if that 
effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the protocol or appli cation (including a supplementary plan or application), or 
any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.  If an adverse event is determined to meet the definition of an 
unantici pated adverse event, the sponsor will immediately conduct an evaluation.  If an 
unanticipated adverse device effect that represents an unreasonable risk for subject health or 
a product performance failure becomes apparent, immediate action will be taken an d the 
appropriate authorities will be notified.  The investigator will be notified of the results of this evaluation.  All unanticipated device -related adverse effects will be reported to all 
investigators.  
21.2. Stroke Reporting  
In the event that a subject expe riences a stroke during the course of the study, supporting 
documentation will be requested by [CONTACT_456].  This information may include neurologist consultation note/s, MRI/CT imaging, radiology reports, additional NIHSS/MRS/Barthel Index evaluations, or  statement from the investigator. In addition, a search for alternative 
causes of stroke (including hypercoagulable work- up) and TEE evaluation at the time of any 
stroke or embolic event is strongly encouraged to help better ascertain the mechanism of all strokes. An optimal TEE evaluation includes, where feasible based on patient status and technical considerations, evaluation of:  
i. LA thrombus  
ii. WATCHMAN Device Seal  
iii. WATCHMAN Device thrombus or pannus  
iv. Agitated saline contrast injection to evaluate presence of residual right to left shunt at 
the atrial level (persistence of PFO or residual puncture hole from transseptal catheterization for device placement)  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 47 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 48 of 54 
 v. Presence and grade of ascending and arch aortic atheroma 
vi. Presence of worsening left ventricular dysfu nction, “new” regional wall motion 
abnormality or presence of LV thrombus (LVEF data may be supplemented by [CONTACT_446638], in addition to TEE parameters above)  
21.3. Device Thrombus 
The most accurate determination of whether thrombus has formed on the s urface of the 
WATCHMAN device is through TEE evaluation.  In the case of thrombus on the atrial 
facing side of the device, anticoagulation therapy should be initiated for approximately [ADDRESS_567918] 
becoming aware of the event.  Device deficiencies are not to be reported as adverse events. However, if there is an adverse event that results from a device deficiency, that specific event would be recorded on the appropriate eCRF.  If possible, the device(s) should be returned to BSC for analysis. Instructions for returning the investigational device(s) will be provided. If it is not possible to return the device, the investigator should document why the device was not returned and the final disposition of the device. Device deficiencies should also be documented in the subject’s medical record.  
21.5. Reporting to Regulatory Authorities / IRBs / ECs / Investigators  
BSC is responsible for reporting adverse event information to all participating investigators and regulatory authorities, as applicable. The Principal Investigator [INVESTIGATOR_5703] , and regulatory authorities of UADE and SAE as required by 
[CONTACT_5737] /regional regulations . 
22. Committees 
22.1. Safety Monitoring Process  
To promote early detection of safety issues, the CAP 2 CEC will provide evaluations of safety events. Success of this program requires dynamic collection of unmonitored data as soon as the event is reported. This is expedited through [LOCATION_011] Scienti fic’s Global Safety 
Office, which is responsible for coordinating the collection of information for the subject dossier from the centers. During regularly scheduled monitoring visits, clinical research 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 48 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 49 of 54 
 monitors will support the dynamic reporting process through their review of source document 
information. 
22.2. Clinical Events  Committee  
A Clinical Events Committee (CEC) is an independent group of individuals with pertinent 
expertise that reviews and adjudicates important endpoints and relevant adverse events 
reported by [CONTACT_2792]. The CEC will review a safety event dossier, which may 
include copi[INVESTIGATOR_446613]. CEC responsibilities, 
qualifications, membership, and committee procedures are outlined in the CEC char ter. The 
CECs classifications of the adverse events will be used in all study reports, evaluation of study endpoints and in all data analyses.  
22.3. Data and Safety Monitoring Board  
An independent Data and Safety Monitoring Board (DSMB) will be established for the 
review of data and safety parameters in the study.  The DSMB will develop a charter and stoppi[INVESTIGATOR_17781].  The members will consist of at least four physicians in specialties of electrophysiology, interventional cardiology, or neurology.  A t least one 
member of the committee will be a biostatistician.  
The DSMB will function in accordance with Guidance for Clinical Trial Sponsors: 
Establishment and Operation of Clinical Trial Data Monitoring Committees.  Meeting frequency will be determined by [CONTACT_446639].   
The DSMB will be utilized to review data from the continued access study until the time of 
commercialization of the WATCHMAN device.  
23. Suspension or Termination  
This study ma y be terminated at any time.  Upon completion or termination, all data and 
unused investigational devices must be returned to the sponsor  
23.[ADDRESS_567919] Research, BSC will submit study results f or publication 
(regardless of study outcome) following the conclusion or termination of the study. [LOCATION_011] Scientific Corporation adheres to the Contributorship Criteria set forth in the Uniform Requirements of the International Committee of Medical Journal Editors (ICMJE; http://www.icmje.org). In order to ensure the public disclosure of study results in a timely manner, while maintaining an unbiased presentation of study outcomes, BSC personnel may 
Released [ADDRESS_567920] authors and investigators in publication preparatio n provided the following guidelines 
are followed.  
• All authorship and contributorship requirements as described above must be 
followed. 
• BSC involvement in the publication preparation and the BSC Publication Policy 
should be discussed with the Coordinating P rincipal Investigator(s) and/or 
Executive/Steering Committee at the onset of the project.  
• The First and Senior authors are the primary drivers of decisions regarding 
publication content, review, approval, and submission.  
24. Bibliography  
1 Hankey GJ. Non- valvular Atrial Fibrillation and Stroke Prevention.  MJA  2001; 174:234-
348.  
2 Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le  
Heuzey J- Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith 
SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J -J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres 
C, Dic kstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. 
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Pract ice Guidelines and the European Society of Cardiology Committee for Practice 
Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol  2006;48:e149 –246. 
 
3Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during 
aspi[INVESTIGATOR_446614]: analysis of 2012 participants in the SPAF I- III clinical 
trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke  
1999;30:1223–9. 
 
4White, Harvy D., DSc; Gruber Michael, MSc; Feyzi, Jan, MS; et.al.,  Comparison of 
Outcomes Among Patients Randomized to Warfarin Therapy According to Anticoagulant Control:  Results from SPORTIF III AND V.,  Archives of Internal Medicine , Feb. 12, 2007, Vol.167., pg 239- 245. 
 
5Connolly, Stuart J., Pogue Janice, MA, MSc; Eikelboom, John, MBBS, MXc, 
FRACP,FRCPA, et.al.,  Benevit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ra tion Control Achieved 
by [CONTACT_446640], Circulation, 2008;118:2029- 2037. 
 
[ADDRESS_567921] and patient foramen ovale closure devices in 1,000 consecutive patients.  J. Am. 
Coll. Cardiol . 2004; 43; 302- 309. 
  
Released [ADDRESS_567922] media  
 
Anemia requiring 
transfusion  
 
Anesthesia risks and complications  
   
Arrhythmias  
 
 
AV fistula  
 
 
Cardiac 
perforation/tamponade  
 
Chest pain/discomfort  
 
Complete heart block  
 
 
Cranial bleed  
 
Death  
   
Endocarditis  
 
Gastrointestinal bleeding  
 Groin puncture bleed  
 
 
Hematoma  
 
 
 Hyper/Hypotension  
 Obstruction of the circulation by [CONTACT_446641]  
 
A response such as rash, hives, itching, asthma, hay fever, anaphylaxis, etc., to 
contrast media  
A drop in hemoglobin that results in transfusion of 2 or more units of packed 
red blood cells  
 
   Complications and risks of general anesthesia include but are not limited to: 
difficulties with the lung, heart, and liver or nerve functions. Serious illness, 
additional surgery and even death may result from the complications of general 
anesthesia  
 
An alteration in rhythm of the heartbeat that requires treatmen t with a device or 
anti-arrhythmic medication   
 A communication between an artery and vein in which arterial blood flows 
directly into a vein or is carried into a vein by a connecting pathway  
 
See Pericardial Effusion  
 
 
Pressure, heaviness and/or sharp pain in the chest region  
 
Also known as third- degree heart block or complete AV block, it is a condition 
in which none of the electrical impulses can reach the ventricles  
 
Asymptomatic intracranial bleed  
 
A death is defined as a cardiovascular death if the death is from a 
cardiovascular event including sudden death, MI, cardiac arrhythmia, and heart failure  
 
Inflammation of cardiac tissue (endocardium)  
 
Bleeding with an origin within the gastrointestinal system  
 
Bleeding or oozing of blood from the groin ac cess site used for the implant 
procedure  
 A mass of usually clotted blood that forms in a tissue, organ, or body space as a result of leakage from a blood vessel that requires additional treatment beyond 
applying pressure  
 
Elevated blood pressure exceeding  140 over 90 mmHg, or low blood pressures 
less than 90 over 50 mmHg  
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 52 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 53 of 54 
  
Term Definition  
 
Infection  
 
 
 
Major bleeding requiring 
transfusion  
 
Myocardial infarction  
 
  
 
  
 
  
 
 Pericardial effusion  
  
 
 
 
 
 
 
Pleural effusion  
 
Pneumothorax  
  Pseudoaneurysm 
 
 
Pulmonary edema  
 Pulmonary embolism  
 
 
  
Pulmonary vein obstruction  
 
Renal insufficiency/failure  
 Stroke  
  
The invasion of the body by [CONTACT_446642], e.g., endocarditis, pericarditis, sepsis  
 
Non site -specific bleeding requiring the transfusion of 2 or more units packed 
red blood cells  
 
Either one of the following criteria satisfies the diagnosis for an acute, evolving 
or recent MI:   
1)  Typi[INVESTIGATOR_446615] (troponin) or more rapid rise and fall 
(CK-MB) of biochemical markers of myocardial necrosis with at least 
one of the following:  
a) ischemic symptoms;  
b) development of pathological Q waves on the ECG;  
c) ECG changes indicative of ischemia (ST segment elevation or 
depression); or  
d) Coronary artery intervention (e.g. coronary angioplasty).  
2)  Pathologic findings of an acute MI  
 
Pericardial effusions are defined by [CONTACT_446643].  
Pericardial Effusion:  An observed pericardial effusion not necessi tating 
percutaneous drainage nor surgical repair.  
Pericardial Effusion with Tamponade:  A pericardial effusion resulting in 
percutaneous treatment/drainage.  
Cardiac Perforation:  A pericardial effusion resulting in surgical 
intervention/repair.  
 
Fluid in a  pleural cavity  
 
An abnormal state characterized by [CONTACT_446644] (as air) in the pleural 
cavity  
 Extra -vascular fluid sac without vascular wall lining but with communication 
with arterial vessel  
 
Abnormal accumulation of fluid in the lungs  
 
Embolism  of a pulmonary artery or one of its branches that is produced by 
[CONTACT_446645] a blood clot originating in a vein of the leg or 
pelvis and that is marked by [CONTACT_446646], chest pain, fainting, rapid heart 
rate, cyanosis, shock, and sometimes death  
 
An obstruction in the pulmonary vein that can decrease blood flow to the atria  
 50% increase in creatinine level or requiring dialysis  
 Ischemic Stroke: Sudden onset of a focal neurological deficit with symptoms 
and/or signs persisting more than 24 hours or symptoms less than 24 hours with 
Released 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 53 of 54
  Confidential 
 
[LOCATION_011] Scientific  
CAP2 Protocol  
PDM  90884521 RevAF 
Page 54 of 54 
  
Term Definition  
 
 
 Systemic embolism  
   
 
 
Thromboembolism  
 
 
Thrombosis  
 
Thrombosis at septal 
puncture  
 
Transient ischemic attack 
(TIA) 
  
Valvular damage  
 
Vascular damage  
 
Vasovagal reactions  
 
 
Wound dehiscence  CT or MRI evidence of tissue loss without hemorrhage.  
Hemorrhagic Stroke: Symptomatic intracranial hemorrhage due to any cause.  
 
Abrupt vascular insufficiency associated with clinical or radiologic evidence  of 
arterial occlusion in the absence of other likely mechanisms (e.g., atherosclerosis, instrumentation).  In the presence of atherosclerotic peripheral vascular disease, diagnosis of embolism to the lower extremities requires 
arteriographic demonstration  of abrupt arterial occlusion.  
 The blocking of a blood vessel by a particle that has broken away from a blood 
clot at its site of formation  
 
The formation or presence of a blood clot within a blood vessel  
 
The formation or presence of a blood clot at the location of septal puncture 
during the implant procedure  
 
Acute focal neurological event (including focal motor deficit aphasia, difficulty 
walking, hemi sensory deficit, amaurosis fugax, blindness, or focal visual 
deficit) lasting at least 5 minutes and u p to 24 hours that is imaging negative   
 
Damage to the valves within the heart  
 
Damage to the walls of the vessels  
 
A fainting or loss of consciousness response generally due to a sudden drop in 
blood pressure, syncope, or other external stimuli 
 
The part ing of the sutured lips of a surgical wound typi[INVESTIGATOR_446616] 90884521 AF.6 CAP2 Protocol
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 54 of 54